Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to the Prescribing Information in Korea.

Next Previous
Search
Trial Profile

Safety of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix When Administered According to the Prescribing Information in Korea.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RIX 4414 (Primary)
  • Indications Rotavirus infections
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline; GSK

Most Recent Events

  • 06 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 28 Jun 2012 Actual patient number changed from 876 to 1052 according to ClinicalTrials.gov.
  • 24 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top